-
公开(公告)号：US12121540B2
公开(公告)日：2024-10-22
申请号：US17030335
申请日：2020-09-23
IPC分类号： A61K35/17 , A61K31/4196 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00 , A61P37/04 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/4196 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P35/00 , A61P37/04 , C12N5/0636 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , C12N2501/72 , C12N2506/11
摘要： Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions using novel Cbl inhibitors for the propagation of cells desirable for use in cell-based immunotherapies.
-
公开(公告)号：US11951133B2
公开(公告)日：2024-04-09
申请号：US17864307
申请日：2022-07-13
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/193 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61N5/1001 , A61N5/1077 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/022 , C12N5/0636 , A61K2039/5152 , C12N2501/2302 , C12N2501/998 , C12N2501/999
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
3.发明公开公开(公告)号：US20240025923A1
公开(公告)日：2024-01-25
申请号：US18346745
申请日：2023-07-03
IPC分类号： C07D519/00
CPC分类号： C07D519/00
摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
-
公开(公告)号：US20230150991A1
公开(公告)日：2023-05-18
申请号：US17853904
申请日：2022-06-29
发明人： Arthur T. SANDS , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D413/14 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D471/04
CPC分类号： C07D413/14 , C07D401/14 , C07D403/10 , C07D403/12 , C07D405/14 , C07D471/04
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US20220339152A1
公开(公告)日：2022-10-27
申请号：US17716982
申请日：2022-04-08
IPC分类号： A61K31/502 , C07K16/28 , C12N5/0783 , A61K31/5025 , A61K31/454 , A61P35/00 , A61K31/337
摘要： The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds. Also provided are methods of using the combinations with Cbl-b compounds and compositions thereof, such as in therapeutic methods.
-
公开(公告)号：US20210085717A1
公开(公告)日：2021-03-25
申请号：US17030258
申请日：2020-09-23
IPC分类号： A61K35/17 , A61P35/00 , A61K31/454 , A61K31/4545 , A61K31/506 , A61K31/4196 , A61K31/5377 , C12N5/0783
摘要： Methods and compositions using novel Cbl inhibitors enhancing expansion of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions.
-
公开(公告)号：US12091426B2
公开(公告)日：2024-09-17
申请号：US18054118
申请日：2022-11-09
发明人： John Buell , Frederick Cohen , Ryan Pemberton , Hunter P. Shunatona , Lan Wang , Mark Edward Zak
IPC分类号： C07D519/00
CPC分类号： C07D519/00
摘要： The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
-
公开(公告)号：US20240293458A1
公开(公告)日：2024-09-05
申请号：US18443228
申请日：2024-02-15
发明人： Arthur T. SANDS , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/19 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61N5/10 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/02 , C12N5/0783
CPC分类号： A61K35/17 , A61K31/438 , A61K31/454 , A61K31/4545 , A61K33/243 , A61K35/761 , A61K35/763 , A61K35/768 , A61K38/193 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K45/06 , A61N5/1001 , A61N5/1077 , A61P35/00 , C07D401/14 , C07D405/14 , C07D471/04 , C07D491/107 , C07F5/022 , C12N5/0636 , A61K2039/5152 , C12N2501/2302 , C12N2501/998 , C12N2501/999
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US12049471B2
公开(公告)日：2024-07-30
申请号：US18068195
申请日：2022-12-19
发明人： Arthur T. Sands , Neil F. Bence , Christoph W. Zapf , Frederick Cohen , Chenbo Wang , Thomas Cummins , Hiroko Tanaka , Hunter Shunatona , Mario Cardozo , Dahlia Weiss , Jennifa Gosling
IPC分类号： C07D498/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/08
CPC分类号： C07D498/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D491/08
摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
-
公开(公告)号：US20240124475A1
公开(公告)日：2024-04-18
申请号：US18374282
申请日：2023-09-28
发明人： Daniel W. Robbins , Arthur T. SANDS , Joel MCINTOSH , Jeffrey MIHALIC , Jeffrey WU , Daisuke KATO , Dahlia WEISS , Ge PENG
IPC分类号： C07D487/10 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/10
CPC分类号： C07D487/10 , C07D401/14 , C07D413/14 , C07D417/14 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/10
摘要： The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.02 秒)
